Selective Inhibition of Enzyme Isoforms of Nitric Oxide Synthetase

University of California, Irvine researchers have discovered a method to design and use selective inhibitors against a family of nitric oxide synthetase isoforms that control the production of nitric oxide (NO). X-ray crystallography was utilized to generate isoform specific NOS-inhibitor complexes with unique structural characteristics. An overproduction of NO has been linked to several diseases, conditions and addictions, including: ischemic injury and other brain damage after stroke, migraine headache, Alzheimer's Disease, colitis, tissue damage, inflammation, septic shock and rheumatoid arthritis. Application: This discovery provides for drug discovery and design protocols for isoform drugs that target NOS isoforms and reduce NO production.

Patents:
US 7,056,945

Type of Offer: Licensing



« More Biotech Patents

---